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Abstract: Women are the most affected by genital herpes, which is one of the most common sexually
transmitted infections, affecting more than 400 million people worldwide. The application of vaginal
microbicides could provide a safe method of protection. Acyclovir is a safe and effective medication
for vaginal administration, and numerous benefits have been observed in the treatment of primary
or recurrent lesions due to genital herpes. Vaginal tablets based on a combination of the polymers
iota-carrageenan and hydroxypropyl methylcellulose were developed for the controlled release of
acyclovir. Swelling, mucoadhesion and drug release studies were carried out in simulated vaginal
fluid. The tablets, containing a combination of iota-carrageenan and hydroxypropyl methylcellulose,
have an adequate uptake of the medium that allows them to develop the precise consistency and
volume of gel for the controlled release of acyclovir. Its high mucoadhesive capacity also allows the
formulation to remain in the vaginal area long enough to ensure the complete release of acyclovir.
These promising formulations for the prevention of genital herpes deserve further evaluation.
Keywords: genital herpes; acyclovir controlled release; mucoadhesive vaginal tablets; marine
polymers; iota-carrageenan; hydroxypropyl methylcellulose
1. Introduction
Sexually transmitted infections (STIs) are among the most common communicable conditions and
affect the health and lives of people worldwide. The World Health Organization (WHO) estimates there
are more than 1 million new curable STIs every day [1]. Genital herpes is one of the most widespread
sexually transmitted infections in the world. Herpes simplex virus 2 (HSV-2) is the main cause of this
disease [2]. It has been estimated that around 400 million people are infected with HSV-2 worldwide,
and that approximately 20 million new cases occur each year [3]. More women than men are infected
with HSV-2, as sexual transmission of HSV is more efficient from men to women than vice versa. It is
a global threat to public health [4]. HSV-2 and Human Immunodeficiency Virus (HIV) have been
shown to influence each other; HSV-2 infection increases the risk of acquiring a new HIV infection by
approximately three-fold [5,6], and up to eight-fold if the exposure occurs soon after acquiring the
HSV-2 infection [7,8].
Although there are definite therapies for the treatment of viral infections such as HSV-2, there is
no cure for this disease. A viable strategy today is, therefore, to develop effective methods to prevent
the spread of STIs, of which one of the most promising is the use of microbicides. Microbicides are
chemical agents used topically by women within the vagina to prevent the spread of STIs, including
HIV. The most commonly used vaginal dosage forms include gels, tablets and vaginal rings [9]. There is
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currently no effective microbicide, and many vaginal microbicide formulations do not cause the desired
response due to certain limitations such as leakage, messiness, relatively low residence time, low dose
accuracy and low stability, giving rise to an inadequate formulation and hence a lack of effectiveness.
Additionally, STI prevention techniques do not reach all women, especially in developing countries,
where the prevalence of sexually transmitted infections is high [4,10]. The development of a vaginal
microbicide to effectively prevent the sexual acquisition of viruses and reduce new cases of HSV
infection in women could be a safe method of protection for women and their partners. Unlike male or
female condoms, microbicides are a potential preventive option that can be easily controlled by women
themselves, and do not require the cooperation, consent or even the knowledge of their partner [11–13].
Acyclovir (ACV), a synthetic purine nucleoside analogue derived from guanine, was the first
antiviral drug to specifically target a viral enzyme, DNA polymerase, to inhibit DNA chain elongation,
and is one of the most effective and selective antiviral drugs. ACV has an antiviral effect on the herpes
simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2) and varicella zoster virus (VZV) by interfering
with DNA synthesis and inhibiting viral replication [14]. ACV is a safe and effective drug for vaginal
administration, used in the treatment of primary or recurrent genital herpes lesions. A clinical study
by Corey et al. showed that topical acyclovir shortens the duration of viral shedding and accelerates
healing of some genital herpes simplex virus infections [15–17], as well as preventing transmission of
genital herpes. Different dosage forms containing ACV have been evaluated, including tablets [15,18],
gels [19], intravaginal rings [20], microporous matrices [21] and nanoparticles [22].
Tablets offer many advantages, such as portability, precise dosing, high stability, ease of storage,
handling and administration and feasibility of large-scale production at a low cost compared
to semi-solid systems. Semi-solid systems have several limitations such as leakage, discomfort,
complicated application and low residence time, and they may provide unsuitable doses due to the
heterogeneous distribution [12,23]. Some reported solutions, such as liposomal delivery systems
for vaginal administration of ACV, apart from the previously indicated disadvantages, have a low
percentage of drug encapsulation efficiency and low stability of the liposomes in simulated vaginal
fluid (SVF), due to the components of the acidic medium that induce a fast drug release. Thus limiting
their application [24,25]. On the contrary, tablets could therefore be useful for the controlled release of
ACV using polymers of natural or semi-synthetic origin [26]. The main advantage of these polymers is
their biocompatibility, biodegradability and non-toxicity [27].
There is currently a widespread trend to seek raw materials in marine resources that can be
successfully incorporated into biomedical applications. These resources include algae, crustaceans and
other microorganisms, all of which provide compounds called marine polymers. Marine polymers
are divided into three important groups, polysaccharides, proteins and lipids, and can be
used for biomedical applications, such as in regenerative medicine and as delivery vehicles for
controlled/sustained drug release, as well as for tailored biomaterials [28,29].
The priority focus in the study of biopolymers is on marine polysaccharides, which are important
due to their sources and their ease of acquisition as a renewable resource. Seaweeds are the main
source of marine polysaccharides such as alginates, fucoidans, laminarin, agar, carrageenans, galactans
and ulvan [30]. Carrageenan, agar and alginate are the marine origin polysaccharides most widely
used commercially [31].
Carrageenans are a group of linear sulphated polysaccharides present in the cell structure
of Rhodophyceae algae. All carrageenans have a high molecular mass and are a linear sulphated
polysaccharide of D-galactose and 3,6-anhydro-D-galactose (3,6-AG) linked by a-1,3 and b-1,4-glycosidic
bonds, commonly used in the pharmaceutical industry for the development of hydrogels due to their
high viscosity, gelling ability and stabilizing properties [32–34]. They can be classified into three
main types: kappa, iota and lambda, depending on the number and position of the sulphate groups.
The content of 3,6-anhydro-D-galactose (3,6-AG) determines the characteristics of the different types of
carrageenan, and high levels of ester sulphate imply a lower gelling force and a lower solidification
temperature [32,35]. Iota-carrageenan (iota-CG) contains 28% to 35% ester sulphate and 25% to 30%
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3,6-AG units, and forms colloids and gels in aqueous media at very low concentrations. These gels
are transparent and thermoreversible, and can be either elastic and cohesive or firm and fragile,
depending on the combination of fractions used [33–36]. Carrageenans have been used in several
studies, with effective results in vaginal administration, such as the vaginal gels containing carrageenan
studied for the inhibition of the human papillomavirus (HPV), which showed that carrageenan has
activity against HPV [37–39]. Another study demonstrated the advantage of combining carrageenan
with Griffithsin, which acts as a broad-spectrum microbicide against HSV-2 and HPV in vitro and
in vivo [40,41]. There is also evidence that carrageenan-based gel offers protection against HSV-2
transmission by binding to herpes virus receptors [42–44]. A number of reports focus on adding
carrageenan to other polymers to leverage the gelling properties of carrageenan and achieve a good
controlled-release profile [15,45]. The addition of carrageenan significantly decreased the erosion rate
of a poloxamer 407-based gel, improved the sustained-release properties of acyclovir, and exhibited a
synergistic bioadhesive effect with Carbopol® in vivo [45].
Hydroxypropyl methylcellulose (HPMC) is a cellulose derivative that is widely included in
hydrophilic matrix applications due to its stability, independent pH performance, worldwide regulatory
acceptance and its versatility in the application of various pharmaceutical forms for controlled
release [13,46–48]. Tablets formulated only with HPMC have shown an ex vivo mucoadhesion time
of over 70 h and a sustained and complete drug release of over 40 h, confirming its applicability in
the vaginal environment [49]. Hydroxypropyl methylcellulose has been incorporated into vaginal
formulations such as gels [50], films [47,51] and tablets [15,52], exhibiting good mucoadhesion and
a controlled release of antimicrobial drugs such as ACV [53], tenofovir [13], fluconazole [54] and
clotrimazole [55].
Against this background, and since women are more affected by HSV—as sexual transmission of
the virus is easier from men to women than vice versa—the aim of this study was to develop vaginal
tablets loaded with ACV based on a combination of iota-CG, a polymer of marine origin with proven
antiviral capacity, and HPMC, a semi-synthetic polymer, in order to obtain mucoadhesive tablets with
ACV controlled release to protect women from the high incidence of HSV, and thus, comply with WHO
guidelines [4].
2. Results and Discussion
2.1. Preparation of the Tablets
In the present study, eight batches of tablets with varying concentration of polymer (iota-CG,
HPMC) and magnesium stearate were prepared, each tablet weighing 328 mg (drug included) and
blank batches (without drug) of 228 mg weight. The composition of each batch (mg/tablet) is shown in
Table 1. The tablets were cylindrical in shape (with an average diameter of 13 mm) and their height
was directly weight-related; the heights of the tablets were 1.8–2.0 mm.
Table 1. Composition of the batches prepared in mg/tablet. ACV: Acyclovir.
Batch Iota-Carrageenan HydroxypropylMethylcellulose Magnesium Stearate ACV
I 225 3
H 225 3
IH1 135 90 3
IH2 90 135 3
ACV-I 225 3 100
ACV-H 225 3 100
ACV-IH1 135 90 3 100
ACV-IH2 90 135 3 100
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2.2. Infrared Spectroscopy
The spectroscopic characterization of the raw materials, the blank tablets and tablets with ACV by
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy is shown in Figure 1.
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polymer-MgSt are compatible, i.e., there are no signs of degradation of any of the components. How-
ever, there is a notable decrease in the band centered at 801 cm-1, corresponding to the sulfonic group 
in the tablet formulated with iota-CG (marked with an asterisk). No significant modifications are seen 
in the spectra on the tablet formulated with HPMC and the raw material itself or between HPMC and 
iota-CG when the two polymers are present. 
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at 1709 cm-1; the bands corresponding to the amino groups occur at 1630 cm-1 and 1609 cm-1 [58]. The 
prepared batches—ACV combined with iota-CG (ACV-I), ACV combined with HPMC (ACV-H) and 
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Figure 1. ATR-FTIR spectra of raw materials and tablets. (A) Raw materials: ACV, hydroxypropyl
methylcellulose (HPMC), iota-carrageenan (iota-CG), magnesium stearate (MgSt); (B) blank tablets
(H, I, IH1, IH2); and (C) tablets with ACV (ACV-H, ACV-I, ACV-IH1, ACV-IH2).
The fingerprint region of the typical spectra of the raw materials is shown in Figure 1A.
The study of iota-CG by FTIR spectroscopy reveals t e presence of very strong absorption bands
in the 1210–1220 cm−1 region for the ester sulphate group, and the symmetric vibration of the two
sulfonic groups at 847 and 801 cm−1. The glycosidic linkage occurs in the 1010–1080 cm–1 region and
below, at about 947 cm−1, the vibration of the C-O-C bond in the 3,6-anhydro-D-galactose [56]. The IR
spectrum of HPMC indicates the characteristics peaks of cellulose C-O-C at 1060 and 958 cm−1 [57].
The ATR-FTIR analysis of the blank tablets (Figure 1B) confirmed that the polymers and magnesium
stearate (MgSt) do not interact with each other during compression, as polymer-polymer and
polymer-MgSt are compatible, i.e., there are no signs of degradation of any of the components.
However, there is a notable decrease in the band centered at 801 cm−1, corresponding to the sulfonic
group in the tablet formulated with iota-CG (marked with an asterisk). No significant modifications
are seen in the spectra on the tablet formulated with HPMC and the raw material itself or between
HPMC and iota-CG when the two polymers are present.
The incorporation of ACV into the tablets (Figure 1C) maintains the fingerprint region of the
ACV pure material, and the most characteristic bands correspond to the C=O bonds and are centered
at 1709 cm−1; the bands corresponding to the amino groups occur at 1630 cm−1 and 1609 cm−1 [58].
The prepared batches—ACV combined with iota-CG (ACV-I), ACV combined with HPMC (ACV-H)
and ACV combined with iota-CG and HPMC (ACV-IH1 and ACV-IH2)—showed the multiple bands
of ACV and the bands corresponding to the tablets with no drug incorporated, indicating the complete
compatibility of the drug with the polymers and MgSt.
2.3. Swelling Tests
The numerical data on weight gain was used to calculate the degrees of swelling according to the
formula described in the methodolo y section. Figure 2 shows swelling/erosion profiles of each
batch assayed when valuating the change in weight that occurs in the medium.
Each po itiv valu indicates that the percentag of swelling o weight gain is greater than the
initial weight of the dry matrix, while eac negative swelling rat o (SR) value indicates that the weig t
of the s ollen matrix is less than t e weight of the dry matrix due to the eros on or dissolu ion of the
system in th medium.
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given the consistency of the fluid gel that originates I in aqueous medium, as confirmed in the se-
quence of photos in Figure 3. In both cases, the combination of polymers does not allow the constant 
presence of a core for more than 24 h, since after that point, it is impossible to distinguish this struc-
ture due to the higher swelling rate (Figure 3). 
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on the swelling behavior, which reduces the uptake of aqueous medium due to its limited solubility 
in water [24]. ACV-I has a lower swelling profile than I; the structure also tends to erode rapidly and 
is completely eroded after 48 h, as previously mentioned in I, although in these tablets, the presence 
of the core was observed until 24 h (Figure 3). The characteristic non-hydrated core of this polymer 
can be seen in ACV-H, and when ACV is incorporated in the tablet the nucleus can be observed for 
up to 144 h, as its presence further reduces the uptake of the medium. ACV-IH1 and ACV-IH2 
showed less swelling than their blank batches, as seen in the photographs, which show two clearly 
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six hours, and erodes rapidly in acidic med um due to the nature of the polymer, which forms a
fluid gel thanks to the pr sence of the divalent ion of the SVF (Ca++) [59]. Calcium is abl to form
intra-molecular bridges between the sulphate groups of adjacent anhydro-D-galactos nd D-galactose
residues of iota-CG [60], as can b seen in the photos in Figure 3.
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structure with small pores. In contrast, the structure of the swelling control of H has pores in a chan-
nel form (Figure 4B), which clearly differentiates it from the structure of control I. The combination 
of iota-CG and HPMC (batches IH1 and IH2) produces very similar structures to H. This is in line 
with the swelling/erosion profiles described above, which were similar but not superimposable. That 
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H has a slow swelling behavior, and two characteristic zones on this tablet can be distinguished
from the first hours of the test: a gelled outer layer (gummy phase) and an internal area in the vitreous
state (non-hydrated core). The non-hydrated core allows slow swelling as the gel continues to erode,
thanks to the gelled outer layer that protects the core from rapid swelling [49]. The nucleus remains in
the formulation until about 120 h, as shown in Figure 3.
Figure 2A also shows the swelling/erosion profiles of all the batches developed in mixtures of
iota-CG with HPMC. The swelling behavior in batches of tablets containing a mixture of both polymers
is conditioned by the nature of each polymer and the possible interaction between them. It can clearly
be seen that the IH1 and IH2 tablets have the highest swelling rate. This is because the HPMC chains
can swell completely when iota-CG is combined with HPMC, increasing the speed at which they form
a gel and avoiding the permanence of the non-hydrated core observed in the H tablets, given the
consistency of the fluid gel that originates I in aqueous medium, as confirmed in the sequence of photos
in Figure 3. In both cases, the combination of polymers does not allow the constant presence of a core
for more than 24 h, since after that point, it is impossible to distinguish this structure due to the higher
swelling rate (Figure 3).
Figure 2B shows the swelling/erosion profiles of tablets with 100 mg of ACV. The swelling/erosion
profiles are lower than in the blank batches in all cases, demonstrating the influence of the drug on
the swelling behavior, which reduces the uptake of aqueous medium due to its limited solubility in
water [24]. ACV-I has a lower swelling profile than I; the structure also tends to erode rapidly and is
completely eroded after 48 h, as previously mentioned in I, although in these tablets, the presence of
the core was observed until 24 h (Figure 3). The characteristic non-hydrated core of this polymer can
be seen in ACV-H, and when ACV is incorporated in the tablet the nucleus can be observed for up to
144 h, as its presence further reduces the uptake of the medium. ACV-IH1 and ACV-IH2 showed less
swelling than their blank batches, as seen in the photographs, which show two clearly defined areas in
the tablets: an outer layer and a non-hydrated core. This indicates that the behavior of these batches is
very similar to the swelling behavior of H. The presence of ACV clearly allows the formation of this
area that reduces the uptake of the aqueous medium (Figure 3).
These results show that the combination of polymers enhances the swelling behavior when
iota-CG is combined with HPMC, as it improves the swelling rate of iota-CG. The area under the curve
(AUC) also reveals a difference between batches with or without ACV; and in all cases the SRmax and
the AUC of the blank batches were greater, confirming that the presence of ACV modifies the erosion
process. Finally, the tmax vary from 48–72 hours in the batches with or without drug, with the exception
of I and ACV-I, whose tmax was only six hours in both cases, corroborating the rapid degradation of
the formulation.
2.4. Microstructure of Swelling Witnesses
The swelling witnesses were analyzed by scanning electron microscopy (SEM), where the lost
water was substituted by pores in a lyophilization process [61]. As can be seen from the micrographs
in Figure 4, the witness microstructures vary considerably depending on the nature of the polymer.
The micrograph of the swelling control of I (Figure 4A) reveals the formation of a homogeneous
structure with small pores. In contrast, the structure of the swelling control of H has pores in a channel
form (Figure 4B), which clearly differentiates it from the structure of control I. The combination of
iota-CG and HPMC (batches IH1 and IH2) produces very similar structures to H. This is in line with
the swelling/erosion profiles described above, which were similar but not superimposable. That is,
when the batches formed by two polymers swell, the ordination of the HPMC chains predominates
over that of the iota-CG chains, which also corresponds to the formation of a fluid gel from iota-CG
compared to the more viscous gel developed by HPMC, and which is reflected in the numerical values
of SR.
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Figure 4. Electron microscopy micrographs of swelling witnesses of (A) I, (B) H, (C) IH1, (D) IH2,
(E) ACV-I, (F) ACV-H, (G) ACV-IH1 and (H) ACV-IH2.
The incorporation of ACV (Figure 4E–H) did not modify the structures originated by the polymers
formulated alone (ACV-I, ACV-H) or in combination (ACV-IH1, ACV-IH2), since the ACV particles do
not gel and consequently do not modify the arrangement of polymer chains when they swell.
Control I (Figure 4A) has a uniform structure, with round pores that are partially distorted after
the incorporation of ACV (Figure 4E). This characteristic microstructure allows the formulation to
erode easily, as was deduced from its swelling behavior, which did not reach 48 h in the testing media.
The microstructure of the batches formulated solely with HPMC can be described as elongated channels
(Figure 4B) with small pores in their walls in the presence of ACV (Figure 4F), allowing a gradual
uptake of the surrounding medium which is translated into a moderate swelling behavior compared
to the other batches. Moreover, as mentioned in previous sections, the presence of the channels allows
the non-hydrated core to swell slowly as the gel progressively erodes. Water mobility plays a role in
controlling the swelling and erosion of the tablets [13]. The HPMC has a gradual swelling, starting in
the outer layers until it arrives at the nucleus, then progressively hydrates when the external gel has
been eroded and the water reaches the nucleus [13,62].
The most dramatic change in the microstructure occurred in cases where ACV was introduced
in the batches with HPMC and iota-CG (Figure 4C,D,G,H). The characteristic channels of the HPMC
structure appear to be interconnected by means of thin branches that resemble the microstructure
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of the iota-CG, a characteristic that is more pronounced when the drug molecule is incorporated
(Figure 4G). In Figure 4D,H, these branches are less noticeable due to the lower proportion of this
polymer. The influence of HPMC determines the swelling behavior of these formulations (high
swelling), as when iota-CG is mixed with HPMC, they form a microstructure similar to that of H,
which allows a greater uptake of the medium. In this case, the tablets do not have the characteristic
non-hydrated core seen in the tablets with H, but form a structure that evenly captures the medium.
The Figure 5 shows the results obtained from Hg intrusion porosimetry on the swelling witnesses
of all the batches.
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PSDs obtained from the Hg intrusion curves reveal different pore sizes and volumes depending
on the polymer used. The tablets con ining s lely the iota-GC polymer (shown in Figure 5A) have th
minimum pore size values (about 40 µm), whereas the formulations containing the polymer HPMC
also eveal a bim dal distribution with pores of about 100 µm and 50 µm (these latter to a lesser degre ).
The combination of the two polymers produces a monomodal istribution with an intermediate pore
size b tween th two individual polymers. The pore size determines its erosion in acidic medium, thus,
the gel is no less consi tent and crumbles earlier, according to the data studie the swelling est.
When ACV is incorporated into the formulation, the PSDs in Figure 5B differ significantly from
the tablets with no drug included. Al ough the same r nd is observed in the mean pore size (mean
PSD ACV-I < ACV-H), it is notable tha the bimodal character of the PSD of ACV-H is maintained whe
the two polymers are combi ed, especially in the batch containing minimum amount of o -CG,
i.e., ACV-IH2. H wev , instead of a mean PSD between the two p lymers, the maximum pore volume
occurs at about 100 µm Except in the case of the ACV-I formulatio , a decrease in pore volu e can be
seen with the in o por ti n of the ACV ompared to the original tablet with no ACV includ d.
From these observations, it can be c cluded that the amount and type of polym r influence the
pore size and volume, as seen in the SEM micrographs. The pore volume is thus determined by the
amount of iota-CG, since the higher the amount of this polymer, the high r the volume of the pore;
in contrast, the pore volum decreases when there is more HPMC in the combined tablets, and
inc rporation of ACV also stron ly influences the porous prop ties in all cases.
2.5. Drug Release
The ACV release profiles of all the formulations are shown in Figure 6. Sustained release of more
than 24 hours occurs in all cases.
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ACV-I h d a total release in 48 hours, and released 95% in the first 24 h, demonstrating th t rapid
rosion in the acid medium of this tablet produces greater drug release in a shorter tim .
In contrast, ACV-H t bl ts exhibited the best control of ACV release, attaining the complete release
of the drug at 144 h. This i cl arly r lated to th swelli g/erosion profiles of this formul tion, which is
intermediate compared to the other formulations. This formulation also has different zones—a g lled
outer layer and an int r al are in the vitreous t te—which allow a rolonged release f ACV.
For batches ACV-IH1 and ACV-IH2, the total release of ACV occurs at 96 h, represe ting an
intermediat rele se compared to the other formulations. These formulations control the release of
the drug more effectively than ACV-I, thanks to the consistency and volum of the gel formed by this
combin ti . This is supported by the swelling/erosion profiles, since these mixtures have the highest
swelling r te of all the tablets, allowing a faster release compared to ACV-H. There are no significant
difference in the rel ase profiles of ACV-IH1 and ACV-IH2, regardl ss of t amount of HPMC or
iota-CG. This confirms t at the iota-CG/HPMC combination produc s a mixed gel t at can aintain its
properties despite changes in the proportion of t e two p ly ers, already described in other studies
when HPMC is mixed with chitosan or kappa-carragee an [13,15,63,64].
Bas on the release studies, the formulations can therefore have three types of release: a quick
release in the case of ACV-I; an intermediate release in batches with a mixture of polymers ACV-IH1
and ACV-IH2; and a prolonged release with ACV-H, as they offer a sustained release of mor than
90% of the rug over 120 h. The olymer mixture allows the m dulation of the characteristics of each
component; thus, the formulation can be improved to allow controll d release profiles. The control of
t e drug release is due to the nature f the polymers, the pharmaceutical form a d how they act in the
acidic medium of the SVF.
The tablets containing the combination of polymers are the most suitable for our purpose, since,
as they contain the two types of polymers, they allow a controlled release of the drug on the one
hand, and—on the other—they keep the iota-CG in the formulation, which is very important due to its
antiviral properties.
Mathematical models were used to determine the drug release mechanisms. After analyzing each
sample, Korsmeyer-Peppas, Hixson-Crowell and Hopfenberg were found to be the models that best fit
to the experimental results (Table 2).
In the case of the Korsmeyer-Peppas model, when the formulations are cylindrical tablets as in
this research, a value of n ≤ 0.45 means that ACV release follows a pure diffusion (Fickian process),
and a value of n between 0.45 and 0.89 indicates an anomalous transport (combination of simultaneous
processes) where drug diffusion and relaxation of the polymer fibers occur simultaneously. When n
takes a value equal to 0.89, drug release occurs through transport case II; if n > 0.89, drug release occurs
through transport Supercase II. Both Case II and Supercase II involve the structural modification of the
polymer matrix (relaxation of the polymer chains) [65,66]. ACV-I has a value of n > 0.89, meaning it
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follows a Supercase II drug release, implying extreme drug transport. The values of KKP constant
(Table 2) of the ACV-I batch have a much higher value than the other batches that fit this kinetic,
suggesting that ACV release occurs directly through the relaxation of the polymer chains. This was
corroborated with the swelling test, where the formulation forms a fluid gel that does not allow the
prolonged release of the drug for more than 48 h, due to the behavior of iota-CG in the acidic medium.
Table 2. Correlation coefficients obtained when experimental data are fitted to the different mathematical
models and kinetic constants.
Batch
Korsmeyer-Peppas Hixson-Crowell Hopfenberg
R2 KKP n R2 KHC R2 KHF
ACV-I 0.9931 0.1127 0.9633 0.9789 0.0513 0.9917 0.0655
ACV-H 0.9900 0.0279 0.7410 0.9994 0.0045 0.9972 0.0060
ACV-IH1 0.9830 0.0326 0.6474 0.9860 0.0063 0.9919 0.0083
ACV-IH2 0.9960 0.0368 0.6822 0.9961 0.0061 0.9970 0.0081
Batches ACV-H, ACV-IH1 and ACV-IH2 can be fitted to Korsmeyer-Peppas with a good correlation.
In these batches, the n value is between 0.45 and 0.89 in all cases, suggesting that the release of ACV
is due to simultaneous processes, namely the relaxation of the polymer chains and Fickian diffusion
process. The release of ACV occurs because the polymers swell and the ACV diffuses through the
resulting gel. This was confirmed by the data obtained in the swelling test, where batches ACV-IH1 and
ACV-IH2 formed a structured gel with the highest swelling rate of all the batches studied; unlike ACV-H,
which forms a long-lasting gel with an intermediate swelling rate.
ACV-I is the batch with the poorest fit to the Hixson-Crowell model, since it does not maintain its
structure and erodes rapidly, as mentioned in the swelling test. ACV-H, ACV-IH1 and ACHI2 can fit
this kinetics, as in the swelling test, where the structures maintain their shape and their size decreases
over time due to the presence of HPMC, which structures these formulations more effectively.
Finally, the Hopfenberg model confirms that the process of ACV release occurs through
erosion, as shown in Table 2. The correlation coefficients are high in all cases and are related to
the Korsmeyer-Peppas correlation coefficients.
These results indicate that the formulations have simultaneous release processes, including the
relaxation of the polymer chains, erosion and diffusion of ACV through the gel.
Similarity factor (f2) values were used to compare the experimental results (Table 3).
Table 3. Similarity factor (f2) values for the release profiles. Comparisons with significant difference
(f2 < 65) are in bold.
Batch ACV-I ACV-H ACV-IH1 ACV-IH2
ACV-I 23.57 23.62 24.73
ACV-H 60.27 59.99
ACV-IH1 79.11
ACV-IH2 ——
Data were compared from batches with the single polymer and with the polymer combinations in
different ratios. The comparison of batch ACV-I with batches ACV-H, ACV-IH1 and ACV-IH2 showed
no similarity in any case; as already mentioned, this is due to the rapid release of ACV in ACV-I.
Additionally, according to f2 values, there is no similarity either between batches ACV-H, ACV-IH1 and
ACV-IH2, as the batches with the polymer mixture had an intermediate release in both formulations.
In contrast, ACV-IH1 and ACV-IH2 are similar, confirming that there are no significant differences,
regardless of the proportions of polymers in which they are combined.
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2.6. Mucoadhesion Assessment
Figure 7 shows the results of the mucoadhesion forces and work of mucoadhesion for all the
batches. It can be seen that all the formulations can attach to the vaginal mucosa, and that a value of
between 0.16 N and 0.29 N is required to separate the tablets. This confirms the mucoadhesiveness
of all the polymers assayed, thanks to their adhesion mechanisms mediated by hydrogen bonds and
electrostatic interactions [67,68].
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a combinatio of polymers (ACV-IH1 and ACV-IH2). This was also observed in an earlier study where
polymers were tested alone and in mixtures [15].
ce it as erifie t at all t e f r lati s a c a esi e r erties, t e e t ste as t
eter i e l t e re ai e e t t e a i al c sa.
i re 8 shows the residence times of all batches attached to the vaginal mucosa. ACV-I is the batch
with the s ortest residence time, with only 1 our of adhesion. ACV-H shows a good initial adhesion to
the vagi al mucosa a d a residence time of 120 h. In contrast, the tablets with iota-CG/HPMC remain
attached to the mucosa for prolonged periods of time, more than 140 hours in both cases. The higher
the amount of iota-CG, the longer the mucoadhesion time (ACV-IH1 > ACV-IH2). This may be due
to the interaction that occurs whe these two polymers are mixed, allowing the hydrogen bo ds of
HPMC a d the sulphate groups of iota-CG to bind with the mucosa.
I all cases, t e f r lati i teracts it t e a i al c sa a r l s t e resi e ce ti e
f t e ar ace tical sa e, t s re ci se fre e c [69]. c a esi e f r lati s are
recisely o ified release dosage forms, which make it possible to control the place, time, duration or
magnitude of their action [70–73].
We can report that the best results were obtained in the batches containing the combination
of polymers ACV-IH1 and ACV-IH2, since their residence time in the mucosa allows the complete
release of the drug. As their time of permanence exceeds the drug release, the formulation remains
in contact with the patient for longer, thus ensuring that the drug is completely released. Of the two
aforementioned formulations, ACV-IH1 would be a good candidate for future tests, as it contains a
higher percentage of iota-CG, making it suitable as an antiviral adjuvant of the formulation.
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Although ACV-H has a prolonged release that meets the needs of this research, the residence
time is less than the release time, thus, this formulation is not suitable for use in subsequent studies
(Figure 8).
Another circumstance that must be considered is vaginal turnover, a physiological mechanism
whereby foreign elements are removed from the vaginal epithelial environment, with a renewal time
of 96 h [74]. This is a limitation for mucoadhesive systems; however, this would not be a problem in
the case of ACV-IH1 and ACV-IH2, as these tablets release 100% of the drug in 96 h, thus complying
with the proper dosage.
Finally, it was verified that the carrageenan alone does not have prolonged mucoadhesion
times [15], which in our case does not allow its use in controlled release formulations. However,
when iota-CG is associated with HPMC, the combination enhances the properties of each component
and allows both prolonged mucoadhesion times and controlled release.
These proposed vaginal tablets would offer women full protection against the high incidence of
HSV worldwide, and especially in developing countries such as in sub-Saharan Africa which have the
highest incidence in the world, thus conforming to the guidelines proposed by WHO.
3. Materials and Methods
3.1. Materials
Acyclovir (ACV, lot: 701376) was obtained from Lab. Reig Jofré (Toledo, Spain). Iota-carrageenan
(iota-CG, lot: SLBB2304V) was provided by Sigma-Aldrich (St. Louis, MO, USA). Hydroxypropyl
methylcellulose—Methocel® K 100M CR (HPMC, lot: DT352711), MW: 72 × 104 g/mol, was kindly
supplied by Colorcon Ltd. (Kent, UK). Magnesium stearate PRS-CODEX (MgSt; lot: 85269 ALP) was
acquired from Panreac (Barcelona, Spain). All other reagents used in this study were of analytical
grade and used without further purification. Demineralized water was used in all cases.
3.2. Methods
3.2.1. Preparation of Tablets and Infrared Spectroscopy
Vaginal tablets were developed from physical mixtures of iota-CG, HPMC and iota-CG/HPMC
with MgSt. In all cases, each tablet contained 100 mg of ACV. The selection of this amount of drug
is based on a common application in a commercialized vaginal formulation (topical ACV cream at
5% w/w). Blank tablets (without drug) were also prepared in order to evaluate the possible interactions
between both polymers. The tablets were manufactured with a 13 mm diameter (ID) hardened steel
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dry pressing die set for pellet. Each physical mixture was compressed with a constant force of five tons
for four minutes, and the batches were stored in a desiccator until further evaluation. The tablets were
evaluated for weight variation using a precision balance (METTLER® AT 200, Mettler-Toledo S.A.E.,
Barcelona, Spain). Tablets height and diameter were measured using a digital micrometer (INSIZE®
3108-25A, Suzhou, China).
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy was used
to characterize the raw materials, blank tablets and tablets with ACV with a Perkin-Elmer
spectrophotometer instrument equipped with a MIRacle™ accessory designed for ATR-FTIR
measurements (Perkin-Elmer, Waltham, MA., USA) to evaluate the possible polymer-polymer,
polymer-MgSt and polymer-ACV interactions before and after compression.
3.2.2. Swelling Tests
Each batch was evaluated in simulated vaginal fluid (pH = 4.2) [75], using the method described
by Ruiz-Caro et al. [76]. Each tablet was fixed to a stainless-steel disc, 30 mm in diameter, with a
cyanoacrylate adhesive (Loctite®, Henkel, Austria). This preparation was then placed in a beaker
containing 80 mL of SVF, then in a thermostatized shaking water bath (Selecta® UNITRONIC320 OR,
Barcelona, Spain) at 37 ± 0.1 ◦C and at 15 opm. At specific time intervals, the discs were removed
from the medium, placed on filter paper to remove the excess liquid and weighed on a precision
balance until the complete dissolution or erosion of the tablet. Each sample was tested in triplicate.
The swelling ratio (%) for each sample was calculated according to the following Equation (1) [77]:
SR(%) =
(
Ts− Td
Td
)
× 100 , (1)
where Ts corresponds to the weight of the swollen tablet and Td to the weight of the dry tablet.
At t = 6, 24, 48, 72, 96, 120, 144 and 168 h, photographs were taken with a digital camera (Canon®
EOS 100D 18.0 megapixels, Tokyo, Japan), to observe the aspect and evolution of the tablets in contact
with SVF.
3.2.3. Preparation and Characterization of Swelling Witnesses. SEM Microscopy and Hg Porosimetry
In order to differentiate the internal structure adopted by the tablets when introduced in SVF,
swelling witnesses were obtained according to the time in which each sample reaches the maximum
SR, using the same method as in the swelling test. The tablets were fixed to a stainless-steel disc
and immersed in SVF inside a beaker, which was then placed in the thermostatized shaking water
bath (Selecta® UNITRONIC320 OR, Barcelona, Spain) at 37 ± 0.1 ◦C and 15 opm. The tablets were
maintained under these conditions until the maximum SR was reached, previously quantified in the
swelling test. Each tablet was then extracted from the medium and lyophilized (Lio-Labor®; Telstar,
Barcelona, Spain) to obtain the swelling witnesses. Each batch was analyzed by electron microscopy
using a scanning electron microscope SEM (JEOL JSM 6400) at 20 KV, where the samples were previously
prepared by evaporative coating with graphite (Q150T Turbo-Pumped Sputter Coater/Carbon Coater).
The pore size distributions (PSD) of the witnesses were determined by mercury porosimetry using
an Autopore II 9215 (Micromeritics Corp., Norcross, GA, USA). The corresponding PSD data were
calculated from the intrusion curves, assuming cylindrical pore shapes in all cases.
3.2.4. Drug Release
The release of ACV from the batches was evaluated with the method described by
Sánchez-Sánchez et al. [15]. Each tablet was inserted in a borosilicate glass bottle containing 80 mL
of SVF and placed in a thermostatized shaking water bath (Selecta® UNITRONIC320 OR, Barcelona,
Spain), with an experimental temperature of 37 ± 0.1 ◦C at 15 opm. The test was performed in triplicate.
Samples of 5 mL were removed from each bottle at pre-established times and filtered to eliminate
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the particles in the suspension medium; the medium was replaced with the same volume of SVF at
the same temperature. ACV concentrations in the SVF were quantified by UV-Vis spectroscopy at a
wavelength of 251 nm in a Shimadzu® UV-1700 spectrophotometer (Kyoto, Japan).
In order to determine the process of dissolution of the drug from the tablets, the drug
release experimental data were fitted to various model-dependent methods (Korsmeyer-Peppas,
Hixson-Crowell and Hopfenberg models) to investigate the kinetics of drug release from the different
batches [65,66,78,79].
According to Korsmeyer-Peppas, the drug release as a function of time follows Equation (2):
Qt
Q∞
= KKP × tn, (2)
where Qt/Q∞ is the fraction of drug released at time t, KKP is a constant incorporating the structural
and geometric characteristics of the tablet and n is the release exponent [65]. This model defines the
drug release mechanism according to the value of n.
The mathematic model described by Hixson and Crowell can be applied to dosage forms,
where drug release takes place in parallel planes and the dimension of the dosage form is reduced
proportionally, although its shape remains constant [80]. It is expressed as Equation (3), where Q0, Qt
and KHC are the initial amount of drug, the drug released at time t and a constant that includes the
surface-volume relation, respectively:
Q1/30 −Q1/3t = KHC × t, (3)
The Hopfenberg model is applied to surface-eroding dosage forms and is expressed as Equation (4),
where Qt is, again, the drug released at time t and Q0 is the total drug contained. KHF is the Hopfenberg
rate constant, which includes the expression K0/C0a0, where K0 is the erosion rate constant, Q0 is the
initial drug concentration in the dosage form and a0 is half the initial system thickness. nH is the
Hopfenberg exponent, which is related to the geometry and has a value of 1 (for slab), 2 (for cylindrical)
or 3 (for spherical) depending on the system:
Qt
Q0
= 1− [1− kHF × t]nH , (4)
For our tablets, this expression can be summarized in Equation (5):
1− √Q0 −Qt = kHF × t, (5)
The similarity between the dissolution profiles obtained from our tablets was compared using a
model independent index described by Moore and Flanner to establish the effect of the polymers on
ACV release [81]. This similarity factor (f2) was calculated according to Equation (6).
f2 = 50× log

1+ (1n )
n∑
j=1
W j
∣∣∣R j − T j∣∣∣2

−0.5
× 100
, (6)
where n is the number of samples for each dissolution test, Rj and Tj is the drug release percentage
at each time for the reference and test product respectively and Wj is a weight factor (Wj = 1 in this
work). A value for f2 > 65 indicates a similarity between profiles of over 95%, while f2 < 65 denotes
non-similar profiles [79].
3.2.5. Mucoadhesion Assessment
To establish the tablets’ capacity to adhere to the vaginal mucosa throughout the administration
time, the work and force necessary for detachment was assessed using the method described by
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Cazorla-Luna et al. [67]. The mucoadhesion test was assessed with the TA.XTplus Texture Analyzer
(Stable Micro Systems, Godalming, UK). The dry tablets were fixed to a 20 mm stainless-steel probe
with double-sided adhesive tape. Square fragments of 2 × 2 cm of bovine vaginal mucosa (obtained
from a local slaughterhouse) were fixed to a petri dish with cyanoacrylate adhesive. The probe with the
tablet was moved at a speed of 1 mm/s until it came into contact with the mucosa, applying a contact
force of 500 g for 30 s. The probe was then separated from the mucosa at a speed of 0.1 mm/s until the
complete detachment of the tablet. The force applied during the detachment of the formulation was
measured at a rate of 500 pps. The force applied vs. the distance covered by the probe was measured,
and the maximum force required to separate the tablet from the mucosa was recorded.
An ex vivo mucoadhesion test was applied to determine how long the tablets remained adhered
to the vaginal mucosa, according to the method described by Notario-Pérez et al. [13]. A sample of
bovine vaginal mucosa was fixed to an 8.5 cm × 5 cm stainless steel plate with cyanoacrylate adhesive.
Each tablet was then adhered to the mucosa, applying a pressure of 500 g for 30 s. The preparation was
placed at an angle of 60◦ inside a beaker containing SVF, and then in the thermostatized shaking water
bath (Selecta® UNITRONIC320 OR, Barcelona, Spain) at 37 ± 0.1 ◦C and 15 opm. All batches were
evaluated in duplicate, and the residence time of each batch was assessed by visual observation of
the samples.
4. Conclusions
Combinations of different types of polymers allow the development of robust and effective vaginal
tablets capable of controlling the release of ACV and thus useful for preventing genital herpes.
The combination of a marine-origin polymer—iota-CG—with proven antiviral capacity and a
semi-synthetic polymer—HPMC—in vaginal tablets achieves the complete and controlled release of
acyclovir. Of all the formulations tested, the tablets containing iota-CG and HPMC are indicated for
helping prevent the sexual transmission of genital herpes. The microstructure formed by the mixture
of polymers allows an adequate swelling rate, appropriate residence time in the mucosa and controlled
release of acyclovir, making this an effective application for the prevention of genital herpes in women,
thus reducing the spread of HSV through sexual contact.
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